Abstract Background aims The Food and Drug Administration (FDA) currently recommends
at least 4 h of recipient monitoring after T cell infusions to detect early infusion reactions.
Recent catastrophic reactions to 'first-in-man'biologic agents have emphasized the
importance of this rule for initial studies of new products. The value of such monitoring for
better established agents is less obvious. Methods We reviewed infusion-related adverse
events (AE) following administration of ex vivo-expanded T cell products (antigen-specific …